Tyr654
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr654  -  CTNNB1 (human)

Site Information
RNEGVAtyAAAVLFR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447585
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 5 ) , immunoprecipitation ( 4 , 6 , 8 , 17 ) , mass spectrometry ( 9 , 11 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 28 , 30 , 31 , 32 , 33 , 34 ) , mutation of modification site ( 4 , 10 , 17 , 27 , 29 , 36 ) , phospho-antibody ( 2 , 4 , 5 , 6 , 7 , 8 , 17 , 23 , 27 ) , western blotting ( 2 , 4 , 5 , 6 , 7 , 8 , 17 , 23 , 27 )
Disease tissue studied:
breast cancer ( 2 , 10 ) , colorectal cancer ( 7 , 24 , 25 , 26 , 30 , 31 , 34 ) , colorectal carcinoma ( 7 , 24 , 25 , 26 , 30 , 31 , 34 ) , gastric cancer ( 11 , 12 ) , gastric carcinoma ( 11 , 12 ) , leukemia ( 19 , 20 , 27 ) , chronic myelogenous leukemia ( 19 , 20 , 27 ) , lung cancer ( 8 , 13 , 14 , 16 , 33 ) , non-small cell lung cancer ( 8 , 13 , 14 , 33 ) , non-small cell lung adenocarcinoma ( 13 , 14 ) , non-small cell lung adenocarcinoma, surrounding tissue ( 22 ) , non-small cell squamous cell lung carcinoma ( 33 ) , lung cancer, surrounding tissue ( 15 , 18 , 21 ) , pancreatic cancer ( 2 ) , pancreatic carcinoma ( 2 ) , pancreatic ductal adenocarcinoma ( 2 ) , prostate cancer ( 2 , 5 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
FBXL7 (human) ( 2 ) , Src (human) ( 27 )
Putative in vivo kinases:
Abl (human) ( 27 ) , Src (human) ( 8 )
Kinases, in vitro:
Abl (human) ( 27 ) , EGFR (human) ( 35 ) , HER2 (human) ( 35 )
Putative upstream phosphatases:
SHP-1 (mouse) ( 17 )
Treatments:
5-aza-CdR ( 2 ) , acetaldehyde ( 28 ) , HGF ( 29 ) , hydroxyflutamide ( 5 ) , imatinib ( 27 ) , SB216763 ( 27 ) , SKI-606 ( 27 ) , testosterone ( 5 ) , U0126 ( 7 ) , wortmannin ( 5 )

Downstream Regulation
Effects of modification on CTNNB1:
activity, induced ( 29 ) , intracellular localization ( 4 , 10 ) , molecular association, regulation ( 17 , 23 , 27 , 29 , 36 ) , protein stabilization ( 27 )
Effects of modification on biological processes:
cell growth, altered ( 27 , 29 ) , cell growth, induced ( 10 ) , cytoskeletal reorganization ( 23 ) , transcription, altered ( 27 ) , transcription, induced ( 8 , 10 , 17 )
Induce interaction with:
HIF1A (human) ( 8 ) , SMAD2 (human) ( 8 , 23 ) , SMAD2 (mouse) ( 23 ) , Src (human) ( 8 ) , TBN (human) ( 17 ) , TCF4 (human) ( 27 )
Inhibit interaction with:
CDH1 (human) ( 29 , 36 ) , LEF-1 (human) ( 29 ) , Met (human) ( 29 ) , axin 1 (human) ( 27 )

Disease / Diagnostics Relevance
Relevant diseases:
IPF ( 23 )

References 

1

Weng J, et al. (2021) Advanced glycation end products induce endothelial hyperpermeability via β-catenin phosphorylation and subsequent up-regulation of ADAM10. J Cell Mol Med
34227224   Curated Info

2

Moro L, et al. (2020) Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. Nat Cell Biol
32839549   Curated Info

3

Aros CJ, et al. (2020) High-Throughput Drug Screening Identifies a Potent Wnt Inhibitor that Promotes Airway Basal Stem Cell Homeostasis. Cell Rep
32075752   Curated Info

4

Gayrard C, et al. (2018) Src- and confinement-dependent FAK activation causes E-cadherin relaxation and β-catenin activity. J Cell Biol
29311227   Curated Info

5

Górowska-Wójtowicz E, et al. (2017) Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro 40, 324-335
28163245   Curated Info

6

Li CC, et al. (2016) Enhancement of β-catenin activity by BIG1 plus BIG2 via Arf activation and cAMP signals. Proc Natl Acad Sci U S A 113, 5946-51
27162341   Curated Info

7

Lemieux E, et al. (2015) Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene 34, 4914-27
25500543   Curated Info

8

Xi Y, et al. (2013) Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia. Oncogene 32, 5048-57
23246962   Curated Info

9

Rikova K (2012) CST Curation Set: 13330; Year: 2012; Biosample/Treatment: cell line, mixTMT(A549,H3255,MKN45,H3122,,H1703,H1650)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Wagh PK, et al. (2011) β-Catenin is required for Ron receptor-induced mammary tumorigenesis. Oncogene 30, 3694-704
21423209   Curated Info

11

Possemato A (2011) CST Curation Set: 11925; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Possemato A (2011) CST Curation Set: 11926; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Ren H (2011) CST Curation Set: 11772; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Ren H (2011) CST Curation Set: 11791; Year: 2011; Biosample/Treatment: cell line, FAC 13T/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Tucker M (2011) CST Curation Set: 10943; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Tucker M (2011) CST Curation Set: 10952; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Simoneau M, et al. (2011) SHP-1 inhibits β-catenin function by inducing its degradation and interfering with its association with TATA-binding protein. Cell Signal 23, 269-79
20840866   Curated Info

18

Tucker M (2010) CST Curation Set: 10314; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Possemato A (2010) CST Curation Set: 9956; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

20

Possemato A (2010) CST Curation Set: 9953; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

21

Hu Y (2010) CST Curation Set: 8707; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

22

Ren H (2009) CST Curation Set: 8180; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Kim KK, et al. (2009) Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 119, 213-24
19104148   Curated Info

24

Possemato A (2007) CST Curation Set: 3613; Year: 2007; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

25

Possemato A (2007) CST Curation Set: 3614; Year: 2007; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

26

Possemato A (2007) CST Curation Set: 3615; Year: 2007; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

27

Coluccia AM, et al. (2007) Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 26, 1456-66
17318191   Curated Info

28

Sheth P, et al. (2007) Acetaldehyde dissociates the PTP1B-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. Biochem J 402, 291-300
17087658   Curated Info

29

Zeng G, et al. (2006) Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Exp Cell Res 312, 3620-30
16952352   Curated Info

30

Li Y (2006) CST Curation Set: 1264; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Li Y (2006) CST Curation Set: 1265; Year: 2006; Biosample/Treatment: cell line, SW620/TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

32

Guo A (2005) CST Curation Set: 981; Year: 2005; Biosample/Treatment: tissue, lung/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

33

Rikova K (2005) CST Curation Set: 832; Year: 2005; Biosample/Treatment: cell line, NCI-H520/serum starved; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

Li Y (2005) CST Curation Set: 834; Year: 2005; Biosample/Treatment: cell line, SW480/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

Miravet S, et al. (2003) Tyrosine phosphorylation of plakoglobin causes contrary effects on its association with desmosomes and adherens junction components and modulates beta-catenin-mediated transcription. Mol Cell Biol 23, 7391-402
14517306   Curated Info

36

Schuman EM, Murase S (2003) Cadherins and synaptic plasticity: activity-dependent cyclin-dependent kinase 5 regulation of synaptic beta-catenin-cadherin interactions. Philos Trans R Soc Lond B Biol Sci 358, 749-56
12740122   Curated Info